Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRV-300 in active ulcerative colitis
NCT03849599Phase 1Completed
- Sponsor
- Provention Bio
- Start
- Feb 2018
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing PRV-300 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-emergent adverse events at 12 weeks. Started Feb 2018; status: completed.
02
Drugs
CNTO3157
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03849599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03849599.